Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report issued on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Down 4.2 %

Shares of Titan Pharmaceuticals stock opened at $7.01 on Tuesday. The company has a fifty day simple moving average of $7.34 and a 200-day simple moving average of $7.17. Titan Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $16.60. The stock has a market cap of $6.38 million, a price-to-earnings ratio of -0.85 and a beta of 1.33.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.